DR.REDDY'S LABORATORIES LTD.

Dr. Reddy's Laboratories announced that its API manufacturing facility in Mexico, Industrias Químicas Falcón de México, S.A. de C.V., recently underwent a records assessment by the United States Food and Drug Administration (USFDA). The assessment, conducted between July 17, 2026, and September 8, 2026, concluded with the issuance of a Form FDA 2953, which included two observations. Dr. Reddy's stated that it will respond to these observations within the stipulated timeline. This disclosure is made in accordance with SEBI (LODR) Regulations, 2015.

Dr Reddy's Laboratories Ltd has announced the closure of a USFDA inspection at its API manufacturing facility in Mirfield, UK. The inspection, initially disclosed on September 8, 2025, has been classified as 'Voluntary Action Indicated (VAI)'. The USFDA has officially closed the inspection under 21 CFR 20.64(d)(3), indicating a satisfactory outcome for the facility's operations. This classification suggests that while some observations may have been made, they do not currently warrant mandatory regulatory action from the USFDA.

ICICI Prudential Mutual Fund, through its various schemes, has acquired 7,12,884 equity shares of Dr. Reddy's Laboratories Ltd. on August 12, 2026. This acquisition has resulted in the Fund's shareholding exceeding the 5% threshold of the company's paid-up capital. The acquisition was made from an investment perspective, not to gain controlling interest. The total holding post-acquisition stands at 4,20,45,639 shares, representing 5.037% of the total voting capital.

Dr. Reddy's Laboratories Ltd. announced that Mr. Deepak Sapra has resigned from his position as CEO of API and Services and as Senior Management Personnel. His resignation is effective from the close of business hours on November 12, 2026. Mr. Sapra cited pursuing opportunities outside the company as the reason for his departure. He has been with the organization for over 23 years, having joined in 2003. The company has stated that he will continue to support the organization during this transition period to ensure a smooth handover of responsibilities.

Dr. Reddy's Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar for the U.S. market. This approval strengthens the company's global biosimilars portfolio and its presence in the U.S. pharmaceutical market. The biosimilar was developed, manufactured, and submitted by Dr. Reddy's, following a successful Pre-License Inspection (PLI) at its Hyderabad facility. Fresenius Kabi will exclusively commercialize the product in the United States under a separate agreement. The rituximab biosimilar is already commercialized in India, the EU, UK, and over 25 emerging markets, with marketing approvals in Switzerland and Canada.

Dr Reddy's Laboratories Ltd announced that the USFDA has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh. The inspection, conducted from July 20 to July 29, 2026, resulted in the issuance of a Form 483 with three observations. The company stated it will address these observations within the stipulated timeline.

Dr Reddy's Laboratories Ltd has issued a clarification regarding a news item about its gonorrhea drug, NUZOLVENCE® (zoliflodacin), receiving approval from the Thai FDA. The company confirmed the news is correct, stating it pertains to a joint press release with GARDP made on July 27, 2026. This approval follows the US authorization six months prior. Dr Reddy's clarified that this event does not constitute a material event requiring disclosure under SEBI Listing Regulations, emphasizing their commitment to timely disclosures of material information.

Dr Reddy's Laboratories Ltd announced that its members, at the 42nd Annual General Meeting (AGM), approved key resolutions. Dr. K P Krishnan was re-appointed as an Independent Director for a second five-year term from January 7, 2027, to January 6, 2032. Mr. Srikanth Velamakanni was appointed as an Independent Director for a five-year term from July 1, 2026, to June 30, 2031. Additionally, M/s Deloitte Haskins & Sells, LLP was appointed as the Statutory Auditors for a term of five years, commencing from the conclusion of the 42nd AGM until the conclusion of the 47th AGM. All appointees meet the necessary criteria and are not related to existing directors or key managerial personnel.

Dr Reddy's Laboratories Ltd has made available the audio recordings of its earnings call for the quarter ended June 30, 2026. The call was conducted on July 22, 2026. Investors and stakeholders can access the recording via a provided weblink. This intimation is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dr Reddy's Laboratories Ltd announced the grant of 15,933 employee stock options under its Employees Stock Option Scheme, 2018. The grant was approved by the Nomination, Governance and Compensation Committee of the Board of Directors on July 22, 2026. Each option has an exercise price of ₹1,206, based on the Fair Market Value. The options are subject to a 100% vesting schedule at the end of 3 years and can be exercised according to the respective vesting schedule. This move is in line with SEBI regulations for employee benefits.